Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.

Morishita M, Nagashima M, Wauke K, Takahashi H, Takenouchi K.

J Rheumatol. 2008 Mar;35(3):407-13. Epub 2008 Feb 1.

PMID:
18260178
2.

The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.

Dundar U, Kavuncu V, Ciftci IH, Evcik D, Solak O, Cakir T.

J Bone Miner Metab. 2009;27(4):464-70. doi: 10.1007/s00774-009-0055-9. Epub 2009 Mar 20.

PMID:
19301089
3.

Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.

Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A.

Osteoporos Int. 2006;17(5):693-703. Epub 2006 Jan 25.

PMID:
16435076
4.

Efficacy of risedronate in Japanese male patients with primary osteoporosis.

Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.

Intern Med. 2008;47(8):717-23. Epub 2008 Apr 16.

5.

Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study.

Hozuki T, Imai T, Tsuda E, Matsumura A, Yamamoto D, Toyoshima T, Suzuki S, Yamauchi R, Hayashi T, Hisahara S, Shimohama S.

Intern Med. 2010;49(5):371-6. Epub 2010 Mar 1.

6.

Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.

Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Suzuki S, Miura S.

Nephrol Dial Transplant. 2007 Jun;22(6):1593-600. Epub 2006 Oct 13.

7.

Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).

Fujii N, Hamano T, Mikami S, Nagasawa Y, Isaka Y, Moriyama T, Horio M, Imai E, Hori M, Ito T.

Nephrol Dial Transplant. 2007 Jun;22(6):1601-7. Epub 2006 Nov 23.

11.

Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine.

Yonemura K, Fukasawa H, Fujigaki Y, Hishida A.

Am J Kidney Dis. 2004 Jan;43(1):53-60.

PMID:
14712427
12.

Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2.

Otomo H, Sakai A, Ikeda S, Tanaka S, Ito M, Phipps RJ, Nakamura T.

J Bone Miner Metab. 2004;22(5):404-14.

PMID:
15316861
13.

Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.

Fernández-García D, Muñoz-Torres M, Mezquita-Raya P, de la Higuera M, Alonso G, Reyes-García R, Ochoa AS, Ruiz-Requena ME, Luna JD, Escobar-Jiménez F.

J Endocrinol Invest. 2008 May;31(5):416-21.

PMID:
18560259
14.

Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.

Ste-Marie LG, Sod E, Johnson T, Chines A.

Calcif Tissue Int. 2004 Dec;75(6):469-76. Epub 2004 Oct 14.

PMID:
15478000
15.

Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis.

Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S.

J Rheumatol. 2003 Mar;30(3):474-9.

PMID:
12610804
16.

Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.

Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A.

Horm Metab Res. 2008 Apr;40(4):281-5. doi: 10.1055/s-2008-1046787. Epub 2008 Feb 15.

PMID:
18275008
17.
18.
19.

Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.

Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.

Gerontology. 2009;55(3):275-80. doi: 10.1159/000196280. Epub 2009 Jan 22.

PMID:
19158438
20.

Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG).

Sasaki N, Kusano E, Takahashi H, Ando Y, Yano K, Tsuda E, Asano Y.

J Bone Miner Metab. 2005;23(1):41-7.

PMID:
15616893
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk